Factor X
Showing 1 - 25 of >10,000
CytoSorb® Filter to Remove Anticoagulants From Circulation
Recruiting
- Aortic Dissection
- Factor X Inhibition
-
Oslo, NorwayOslo University Hospital
Jan 31, 2022
Depressive Symptoms, Emotion Regulation Trial in Toronto (SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts))
Completed
- Depressive Symptoms
- Emotion Regulation
- SPARX (Smart, Positive, Active, Realistic, X-Factor thoughts)
-
Toronto, Ontario, CanadaYork University
Jan 27, 2023
Eating Behavior Trial in Montréal (Education - Motivational factor)
Recruiting
- Eating Behavior
- Education - Motivational factor
-
Montréal, Quebec, CanadaMcGill University
Jan 24, 2023
Cardiovascular Diseases, Cardiovascular Risk Factor, Diabetes Trial in Montréal (Cardiovascular Health Awareness Program)
Active, not recruiting
- Cardiovascular Diseases
- +2 more
- Cardiovascular Health Awareness Program
-
Montréal, Quebec, CanadaCentre de recherche du CHUM
Aug 29, 2022
Traumatic Hemorrhage, Coagulopathy, Massive Hemorrhage Trial in Hamitlon, London, Toronto (Fibrinogen + PCC, Frozen Plasma)
Recruiting
- Traumatic Hemorrhage
- +2 more
- Fibrinogen + PCC
- Frozen Plasma
-
Vancouver, British Columbia, Canada
- +5 more
Dec 1, 2022
Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma
Not yet recruiting
- Metastatic Colon Adenocarcinoma
- +6 more
- Balstilimab
- +10 more
-
Duarte, CaliforniaCity of Hope Medical Center
Nov 17, 2022
Adeno-Associated Virus (AAV), Blood Coagulation Disorder, Blood Coagulation Disorders, Inherited Trial in United States
Recruiting
- Adeno-Associated Virus (AAV)
- +16 more
- SPK-8016
-
Los Angeles, California
- +13 more
Feb 3, 2022
Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and
Unknown status
- Anticoagulation
- +2 more
- Estimated anticoagulant level (conversion factor x anti-Xa activity)
- (no location specified)
Nov 30, 2020
NSCLC, EGFR G719X, EGFR L861Q Trial in Chongqing (Furmonertinib 160 mg, Q.D.)
Recruiting
- Non-small Cell Lung Cancer
- +3 more
- Furmonertinib 160 mg, Q.D.
-
Chongqing, Chongqing, China
- +2 more
Sep 16, 2022
Intracerebral Hemorrhage Trial in Worldwide (Recombinant Activated Factor VII (rFVIIa), Placebo)
Recruiting
- Intracerebral Hemorrhage
- Recombinant Activated Factor VII (rFVIIa)
- Placebo
-
Burlingame, California
- +48 more
Jan 25, 2023
Surgery Trial in Worldwide (andexanet alfa)
Terminated
- Surgery
- andexanet alfa
-
Phoenix, Arizona
- +55 more
Jun 30, 2022
Heparin Like Effect in Acute Variceal Bleeding
Recruiting
- Coagulation Disorder
- +2 more
- SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
-
Chandigarh, Choose Any State/Province, IndiaPostgraduate Institute of Medical Education and Research
Sep 26, 2021
Hemophilia A Trial in Toronto (Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins
Completed
- Hemophilia A
- Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)
-
Toronto, Ontario, CanadaHospital for Sick Children
May 3, 2021
Data of Current FVIII Prophylaxis Replacement Therapy in Adult
Active, not recruiting
- Blood Coagulation Disorder
- +8 more
- Standard of Care FVIII Replacement therapy
-
San Francisco, California
- +10 more
Feb 18, 2022
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer Trial in Detroit (biological,
Completed
- Metastatic Pancreatic Adenocarcinoma
- +3 more
- Aldesleukin
- +9 more
-
Detroit, MichiganWayne State University/Karmanos Cancer Institute
Mar 30, 2022
Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)
Recruiting
- Neuroblastoma
- GM-CSF + Naxitamab
-
Gainesville, Florida
- +22 more
Aug 29, 2022
Prothrombin Complex Factor Deficiency Trial in Austria, Hungary (Prothrombin complex concentrate (coagulation factors IX, II,
Completed
- Prothrombin Complex Factor Deficiency
- Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)
-
Feldkirch, Austria
- +5 more
Apr 30, 2021
Hemophilia A Trial in Canada, Puerto Rico, United States (Antihemophilic factor, recombinant, manufactured protein-free)
Completed
- Hemophilia A
- Antihemophilic factor, recombinant, manufactured protein-free
-
Los Angeles, California
- +11 more
Apr 23, 2021
Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer AJCC v8 Trial in
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +5 more
- Bevacizumab
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jul 13, 2022
Haemophilia A Trial in Worldwide (Recombinant Factor VIII (Kovaltry, BAY81-8973))
Completed
- Haemophilia A
- Recombinant Factor VIII (Kovaltry, BAY81-8973)
-
New Orleans, Louisiana
- +42 more
Nov 16, 2021
Hemophilia A Trial in Worldwide (efanesoctocog alfa (BIVV001))
Completed
- Hemophilia A
- efanesoctocog alfa (BIVV001)
-
Los Angeles, California
- +41 more
Jan 20, 2023